( ,61.13575668625042)
(with PA,18.81100205730782)
(= ,14.108251542980867)
(p ,14.108251542980867)
(seroma production,14.108251542980867)
(low-dose aspirin,14.108251542980867)
(intake of,11.756876285817388)
(aspirin use,9.40550102865391)
(membrane type,9.40550102865391)
(of low-dose,9.40550102865391)
(significantly higher,9.40550102865391)
(PET imaging,9.40550102865391)
(vitamin A,9.40550102865391)
(25 ,9.40550102865391)
(PA diagnosed,9.40550102865391)
(reported in,7.054125771490433)
(higher than,7.054125771490433)
(of b-carotene,7.054125771490433)
(post-diagnosis use,7.054125771490433)
(four types,7.054125771490433)
(before the,7.054125771490433)
(very rare,7.054125771490433)
(used in,7.054125771490433)
(prognostic factors,7.054125771490433)
(CXCR4-targeted PET,7.054125771490433)
(between post-diagnosis,7.054125771490433)
(months from,7.054125771490433)
(types of,7.054125771490433)
(prolactinoma and,7.054125771490433)
(HER2+ breast,7.054125771490433)
(was reported,7.054125771490433)
(type MR,7.054125771490433)
(TNBC cells.,7.054125771490433)
(diagnosed before,7.054125771490433)
(the age,7.054125771490433)
(of 25,7.054125771490433)
(radiotherapy in,7.054125771490433)
(the intake,7.054125771490433)
(infrared fluorescent,7.054125771490433)
(Shearlet transform,7.054125771490433)
(in BRCA1,7.054125771490433)
(metastatic disease,7.054125771490433)
(and screening,7.054125771490433)
(abbreviated MRI,7.054125771490433)
(association between,6.63291230641413)
(chest wall,5.8377304471659395)
( =,5.8377304471659395)
(increased risk,5.8377304471659395)
(and breast,4.974684229810597)
(history of,4.974684229810597)
